RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT)

Historical Holders from Q4 2019 to Q3 2025

Symbol: RAPT on Nasdaq
Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 16,463,909
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 2,972,512
Holdings value: $76,661,084
% of all portfolios: 0.002%
Number of holders: 3
Number of buys: 1
Number of sells: -1
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Medicxi IV LP	16.9%		$19,446,240		22,352,000		Medicxi IV GP Limited	27 Dec 2024
Deep Track Capital, LP	9.87%		$12,280,920		14,116,000		Deep Track Capital, LP	23 Dec 2024
Redmile Group, LLC	9.9%		$12,121,231		13,932,449		Redmile Group, LLC	31 Dec 2024
TCG Crossover GP II, LLC	9.99%		$11,478,006		13,193,110		TCG Crossover GP II, LLC	27 Dec 2024
Foresite Capital Fund VI LP	9.3%		$10,875,000		12,500,000		Foresite Capital Fund VI, L.P.	23 Dec 2024
RTW INVESTMENTS, LP	8.9%		$10,234,680		11,764,000		RTW Investments, LP	31 Mar 2025
VANGUARD GROUP INC	6.27%	+2%	$7,202,554	+$4,651,367	8,278,798	+1.8%	The Vanguard Group	31 Mar 2025
PERCEPTIVE ADVISORS LLC	4.5%		$5,115,600		5,880,000		Perceptive Advisors LLC	31 Dec 2024
BlackRock, Inc.	1.7%		$2,006,761		2,306,622		BlackRock, Inc.	31 Mar 2025
COLUMN GROUP II, LP	4.9%		$1,395,126		1,603,593		Peter Svennilson	23 Dec 2024
ORBIMED ADVISORS LLC	6.6%	-33%	$28,023,878	-$310,734,477	1,086,618	-91.7%	ORBIMED ADVISORS LLC	30 Sep 2025
FMR LLC	0.4%		$418,041		480,507		FMR LLC	31 Jan 2025

Institutional Holders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	2,972,512	$76,661,084	+$42,075,407			$25.79	3
2025 Q2	1,341,050	$10,728,400	-$158,903,455	$0	$0	$8	2
2025 Q1	131,135,934	$159,984,594	+$4,424,695	$122	$50,386	$1.22	89
2024 Q4	126,888,838	$199,480,129	+$130,912,564	$110,548	$289,930	$1.58	89
2024 Q3	29,799,656	$59,894,847	-$5,399,235	$4,824	$53,667	$2.01	92
2024 Q2	31,808,667	$97,015,342	-$20,514,565	$1,805,295	$2,566,270	$3.05	100
2024 Q1	31,957,297	$286,976,309	-$135,887,644	$9,501,738	$5,811,856	$8.98	120
2023 Q4	34,982,104	$869,312,485	+$6,735,986	$6,006,245	$10,789,870	$24.85	108
2023 Q3	34,763,427	$577,769,050	+$11,319,522	$159,552	$7,116,684	$16.62	96
2023 Q2	34,050,266	$636,743,238	+$14,411,769	$100,980	$7,302,350	$18.7	97
2023 Q1	33,297,098	$610,504,496	+$19,762,513	$394,525	$7,938,210	$18.35	104
2022 Q4	32,051,948	$634,583,743	+$67,138,151	$15,840	$11,202,840	$19.8	92
2022 Q3	29,977,976	$705,685,698	-$6,718,488	$0	$14,473,000	$24.06	96
2022 Q2	29,739,176	$542,744,027	+$30,137,398	$2,281,000	$9,154,000	$18.25	83
2022 Q1	28,022,792	$616,047,645	-$11,376,493	$0	$1,678,000	$21.99	82
2021 Q4	26,299,986	$965,984,248	+$58,612,650	$400,000	$11,048,000	$36.73	96
2021 Q3	24,839,747	$731,027,543	+$65,328,555	$3,245,000	$5,341,000	$31.05	104
2021 Q2	26,596,757	$845,609,249	+$179,542,242	$46,862,000	$48,963,000	$31.79	107
2021 Q1	20,992,943	$466,036,000	+$14,749,147	$3,396,000	$15,020,000	$22.2	77
2020 Q4	20,445,788	$403,803,000	+$1,193,976	$2,827,000	$2,344,000	$19.75	80
2020 Q3	16,829,467	$541,869,734	+$65,277,706	$503,000	$820,000	$32.2	66
2020 Q2	14,821,430	$430,109,022	+$93,891,523			$29.02	52
2020 Q1	11,682,494	$247,909,000	+$53,863,363			$21.27	37
2019 Q4	2,361,079	$64,437,000	+$64,437,000			$27.61	25